New combo shows promise in Hard-to-Treat blood cancer
NCT ID NCT06868654
First seen Apr 26, 2026 · Last updated May 14, 2026 · Updated 3 times
Summary
This phase 3 study tests a new drug combination (belantamab mafodotin plus bortezomib and dexamethasone) against a standard combination (daratumumab plus bortezomib and dexamethasone) in 72 Chinese participants whose multiple myeloma has returned or stopped responding to prior treatment. The main goal is to see which combination delays cancer progression longer. Participants must have measurable disease and be in adequate health (ECOG 0-2).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Beijing, China
-
GSK Investigational Site
Changchun, China
-
GSK Investigational Site
Guangzhou, China
-
GSK Investigational Site
Hangzhou, China
-
GSK Investigational Site
Jinan, China
-
GSK Investigational Site
Nanjing, China
-
GSK Investigational Site
Shenyang, China
-
GSK Investigational Site
Suzhou, China
-
GSK Investigational Site
Tianjin, China
-
GSK Investigational Site
Wuhan, China
-
GSK Investigational Site
Zhengzhou, China
Conditions
Explore the condition pages connected to this study.